Dexcom | DXCM - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Abbott USD 2.13B 281M 2026-06
Align Technology USD 191.32M 13.27M 2026-06
AtriCure USD 9.66M 9.14M 2026-06
Baxter International USD 276M 210M 2026-06
Becton, Dickinson and Co. USD 752M 125M 2026-06
Boston Scientific USD 1.24B 190M 2026-06
Cooper Companies USD -31M 243.8M 2026-03
Dexcom USD 318.3M 63M 2026-06
Edwards Lifesciences USD 519.5M 4.8M 2026-06
Globus Medical USD -45.97M 209.97M 2026-06
Inogen USD -7.79M 728K 2024-09
Insulet USD 129.7M 7.7M 2026-06
Integra LifeSciences USD 41.29M 29.82M 2026-06
J&J USD 7.48B 860M 2026-06
Medtronic USD 2.09B 354M 2026-03
Merit Medical Systems USD 60.4M 16.25M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Solventum Corp USD 181M 96M 2026-06
Stryker USD 1.79B 687M 2026-06
Tandem Diabetes Care USD -13.79M 3.64M 2026-06
Teleflex USD 73.07M 36.04M 2026-06
West Pharmaceutical Services USD 179.1M 2M 2026-06
Zimmer Biomet Holdings USD 344.7M 50.4M 2026-06